On March 29th, Richard Panico and John Diaz joined us for an update on the latest trends in biopharma services. The durability of biopharma investment has been a major area of focus for our CROs and life science tools coverage to start 2022. In this discussion, we debated funding trends, clinical trial demand, the impact of consolidation of the CRO industry, demand for labor, and also discuss the use of data and technology in clinical trials.
